scilit/backend
1
0
Fork 0
Code Issues Pull Requests Actions 12 Packages Projects Releases Wiki Activity
Files
2c6ecc1f9181dc53932b4efda4def06646c4da9e
backend/backend/scripts/seed_data.py
T
34047007@qq.com 3c85ded216
CI / backend (push) Waiting to run
Details
CI / frontend (push) Waiting to run
Details
feat: 生产部署准备 — 构建加速 + 24迁移链分批脚本 + 搜索性能优化 
- Dockerfile 腾讯源 + BuildKit 缓存（backend pip / frontend npm ci），gitea 锁 1.27.1
- .dockerignore 纳入版本管理（防密钥进镜像）
- 新增 migrate_prod.sh：24 个迁移分 4 批执行，含镜像新鲜度 + DB 起点校验
- cb07d6b1df01 移除 search_tsv 回填（延迟到 g0h1i2j3k4l5 统一全量回填）
- 模型 journal_iso/volume/issue/pages → Text（对应迁移 95c18ebf31e4 / 55105f0bb1d7）
- 搜索优化：tsvector 主路径 + COUNT 截断(10000) + pub_date 排序，admin 聚合单查询
- statement_timeout 30s→60s
2026-08-10 00:33:16 +08:00

1068 lines
81 KiB
Python
Raw Blame History

This file contains ambiguous Unicode characters
This file contains Unicode characters that might be confused with other characters. If you think that this is intentional, you can safely ignore this warning. Use the Escape button to reveal them.
"""种子数据：导入标签树 + 期刊列表 + 50 篇文献 + 文献标签关联"""
import asyncio
import json
import os
import sys
from datetime import date, datetime
sys.path.insert(0, os.path.join(os.path.dirname(__file__), '..'))
import uuid
from app.compat import UTC
from sqlalchemy import func, select
from app.core.security import hash_password
from app.db import async_session, engine
from app.models.business import DrugApproval, GuidelineEvidence, GuidelineVersion
from app.models.interaction import UserLiterature, UserNote, UserSubscription
from app.models.literature import GlobalJournal, GlobalLiterature, GlobalLiteratureTag, GlobalTag
from app.models.user import Tenant, User, UserTenant
from app.services.feed_engine import generate_all_feeds
def uid(): return uuid.uuid4()
def d(s): return date.fromisoformat(s) if s else None
async def import_tags():
async with async_session() as db:
existing = (await db.execute(select(func.count(GlobalTag.id)))).scalar() or 0
if existing > 0:
print(f" Tags already exist ({existing}), skipping import")
result = await db.execute(select(GlobalTag))
tags = result.scalars().all()
return {t.path: t.id for t in tags}
with open(os.path.join(os.path.dirname(__file__), 'seed_oncology_tags.json'), encoding='utf-8') as f:
tags_data = json.load(f)
tags_data.sort(key=lambda x: x['level'])
path_to_id: dict[str, str] = {}
count = 0
async with async_session() as db:
for t in tags_data:
parent_id = None
if t.get('parent_path'): parent_id = path_to_id.get(t['parent_path'])
tag = GlobalTag(id=uid(), name_zh=t['name_zh'], name_en=t.get('name_en'),
path=t['path'], level=t['level'], parent_id=parent_id,
tag_category=t['tag_category'], mesh_ui=t.get('mesh_ui'),
is_selectable=(t['level'] <= 2))
db.add(tag)
path_to_id[t['path']] = tag.id
count += 1
await db.commit()
print(f" Tags imported: {count}")
return path_to_id
async def import_journals():
journals = [
("New England Journal of Medicine", "0028-4793", "1", 176.0),
("The Lancet", "0140-6736", "1", 98.4),
("JAMA", "0098-7484", "1", 63.1),
("BMJ", "0959-8138", "1", 93.6),
("Journal of Clinical Oncology", "0732-183X", "2", 42.1),
("Lancet Oncology", "1474-5488", "2", 51.0),
("JAMA Oncology", "2374-2437", "2", 28.7),
("Cancer Discovery", "2159-8290", "2", 29.5),
("Annals of Oncology", "0923-7534", "3", 48.0),
("Clinical Cancer Research", "1078-0432", "3", 11.5),
("Journal of the National Cancer Institute", "0027-8874", "3", 9.6),
("Cancer Cell", "1878-0261", "3", 48.8),
("European Journal of Cancer", "0959-8049", "3", 8.4),
("Cancer Research", "0008-5472", "3", 11.2),
("Nature Medicine", "1078-8956", "2", 82.9),
("Nature Cancer", "2662-1347", "3", 22.3),
("Cancer", "0008-543X", "4", 6.2),
("Blood", "0006-4971", "4", 21.0),
("Leukemia", "0887-6924", "4", 11.4),
("Int J Radiat Oncol Biol Phys", "0360-3016", "4", 7.0),
("Journal of the NCCN", "1540-1405", "4", 11.0),
("Journal of Thoracic Oncology", "1556-0864", "4", 12.5),
("Lung Cancer", "0169-5002", "4", 5.0),
]
async with async_session() as db:
for name, issn, tier, if_ in journals:
db.add(GlobalJournal(id=uid(), name=name, issn=issn, tier=tier, impact_factor=if_, publisher="—"))
await db.commit()
print(f" Journals imported: {len(journals)}")
async def import_literature(tag_map: dict[str, str]):
"""每篇文献附带标签路径列表，自动关联"""
articles = [
{"pmid": 39000101,
"title": "Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC: Final OS Results from FLAURA2",
"abstract": "Osimertinib plus chemotherapy vs osimertinib alone in EGFR-mutated NSCLC. Median OS 42.1 vs 35.8 mo, HR 0.73.",
"authors": [{"family": "Ramalingam", "given": "SS", "affiliation": "Winship Cancer Institute, Emory University"}, {"family": "Cheng", "given": "Y", "affiliation": "Jilin Cancer Hospital"}, {"family": "Zhou", "given": "C", "affiliation": "Guangdong Provincial People's Hospital"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-07-03", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::EGFR", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "终点::OS", "场景::一线"]},
{"pmid": 39000102,
"title": "Atezolizumab SC vs IV in Advanced NSCLC: IMscin002",
"abstract": "Subcutaneous atezolizumab showed comparable efficacy and safety vs IV formulation in pretreated NSCLC.",
"authors": [{"family": "Burotto", "given": "M", "affiliation": "Bradford Hill Clinical Research Center"}, {"family": "Zvirbule", "given": "Z", "affiliation": "Riga East University Hospital"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2025-07-01", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-L1", "研究类型::RCT::2期", "终点::安全性"]},
{"pmid": 39000103,
"title": "Trastuzumab Deruxtecan vs Physician's Choice in HER2-Low mBC: DESTINY-Breast06",
"abstract": "T-DXd superior PFS vs chemo in HER2-low and HER2-ultralow metastatic breast cancer.",
"authors": [{"family": "Curigliano", "given": "G", "affiliation": "European Institute of Oncology, Milan"}, {"family": "Hu", "given": "X", "affiliation": "Fudan University Shanghai Cancer Center"}, {"family": "Dent", "given": "RA", "affiliation": "National Cancer Centre Singapore"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-06-28", "pub_year": 2025,
"tag_paths": ["癌种::乳腺癌", "靶点::HER2", "治疗::靶向治疗::ADC", "研究类型::RCT::3期", "终点::PFS"]},
{"pmid": 39000104,
"title": "Pembrolizumab plus Chemotherapy in Advanced Biliary Tract Cancer: KEYNOTE-966",
"abstract": "Pembrolizumab plus gem/cis improved OS in advanced BTC vs chemo alone.",
"authors": [{"family": "Kelley", "given": "RK"}, {"family": "Ueno", "given": "M"}],
"journal": "The Lancet", "journal_issn": "0140-6736",
"pub_date": "2025-06-25", "pub_year": 2025,
"tag_paths": ["治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "终点::OS", "场景::一线"]},
{"pmid": 39000105,
"title": "Toripalimab plus Chemotherapy as First-Line Treatment for ESCC: JUPITER-06",
"abstract": "Toripalimab plus chemo improved OS and PFS in advanced ESCC vs chemo alone.",
"authors": [{"family": "Xu", "given": "JM"}, {"family": "Li", "given": "J"}],
"journal": "JAMA", "journal_issn": "0098-7484",
"pub_date": "2025-06-20", "pub_year": 2025,
"tag_paths": ["癌种::食管癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "终点::OS", "场景::一线"]},
{"pmid": 39000106,
"title": "Adjuvant Alectinib vs Chemotherapy in ALK-Positive NSCLC: ALINA Updated OS",
"abstract": "Adjuvant alectinib showed sustained DFS benefit vs chemo in resected ALK+ NSCLC.",
"authors": [{"family": "Solomon", "given": "BJ"}, {"family": "Wu", "given": "YL"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-06-15", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ALK", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::辅助"]},
{"pmid": 39000107,
"title": "Neoadjuvant Dostarlimab in dMMR Locally Advanced Rectal Cancer: 3-Year Results",
"abstract": "100% clinical complete response maintained at 3 years with PD-1 blockade alone in dMMR LARC.",
"authors": [{"family": "Cercek", "given": "A"}, {"family": "Lumish", "given": "M"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-06-10", "pub_year": 2025,
"tag_paths": ["癌种::结直肠癌", "靶点::MSI", "治疗::免疫治疗::PD-1", "场景::新辅助", "终点::ORR"]},
{"pmid": 39000108,
"title": "Palbociclib plus Endocrine Therapy vs Chemotherapy in HR+/HER2- mBC",
"abstract": "CDK4/6 inhibitor plus ET showed comparable OS to chemo with better QoL in first-line mBC.",
"authors": [{"family": "Llombart-Cussac", "given": "A"}, {"family": "Perez-Garcia", "given": "JM"}],
"journal": "Annals of Oncology", "journal_issn": "0923-7534",
"pub_date": "2025-06-08", "pub_year": 2025,
"tag_paths": ["癌种::乳腺癌::HR阳性", "靶点::PIK3CA", "治疗::内分泌治疗", "研究类型::RCT::3期", "终点::OS", "场景::一线"]},
{"pmid": 39000109,
"title": "ctDNA-Guided Adjuvant Chemotherapy in Stage II Colon Cancer: DYNAMIC",
"abstract": "ctDNA-informed approach reduced chemo use by 50% without compromising 2-year RFS.",
"authors": [{"family": "Tie", "given": "J"}, {"family": "Cohen", "given": "JD"}],
"journal": "Lancet Oncology", "journal_issn": "1474-5488",
"pub_date": "2025-06-05", "pub_year": 2025,
"tag_paths": ["癌种::结直肠癌", "终点::生物标志物", "场景::辅助", "研究类型::转化研究"]},
{"pmid": 39000110,
"title": "Cilta-cel vs Standard of Care in Lenalidomide-Refractory MM: CARTITUDE-4",
"abstract": "CAR-T cilta-cel significantly improved PFS and OS vs standard triplet in len-refractory MM.",
"authors": [{"family": "San-Miguel", "given": "J"}, {"family": "Usmani", "given": "SZ"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-06-01", "pub_year": 2025,
"tag_paths": ["癌种::血液肿瘤::多发性骨髓瘤", "治疗::免疫治疗::CAR-T", "研究类型::RCT::3期", "终点::OS"]},
{"pmid": 39000111,
"title": "Enfortumab Vedotin plus Pembrolizumab in Cisplatin-Ineligible mUC",
"abstract": "EV+pembro improved OS and PFS vs gem/carbo in first-line cisplatin-ineligible mUC.",
"authors": [{"family": "Powles", "given": "T"}, {"family": "Gupta", "given": "S"}],
"journal": "JAMA Oncology", "journal_issn": "2374-2437",
"pub_date": "2025-05-28", "pub_year": 2025,
"tag_paths": ["癌种::膀胱癌", "治疗::靶向治疗::ADC", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线"]},
{"pmid": 39000112,
"title": "Sotorasib plus Panitumumab vs Standard in KRAS G12C mCRC: CodeBreaK 300",
"abstract": "KRAS G12C inhibitor plus EGFR antibody improved PFS vs standard in pretreated mCRC.",
"authors": [{"family": "Fakih", "given": "MG"}, {"family": "Kopetz", "given": "S"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-05-25", "pub_year": 2025,
"tag_paths": ["癌种::结直肠癌", "靶点::KRAS", "治疗::靶向治疗", "研究类型::RCT::3期", "场景::二线"]},
{"pmid": 39000113,
"title": "Nivolumab in Resected Stage IIB/C Melanoma: CheckMate 76K Final",
"abstract": "Adjuvant nivo showed durable RFS benefit in resected high-risk stage II melanoma.",
"authors": [{"family": "Long", "given": "GV"}, {"family": "Tawbi", "given": "HA"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2025-05-22", "pub_year": 2025,
"tag_paths": ["癌种::黑色素瘤", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::辅助"]},
{"pmid": 39000114,
"title": "Perioperative Durvalumab in Resectable NSCLC: AEGEAN 5Y",
"abstract": "Perioperative durvalumab improved EFS and OS in resectable NSCLC at 5 years.",
"authors": [{"family": "Heymach", "given": "JV"}, {"family": "Mitsudomi", "given": "T"}],
"journal": "Lancet Oncology", "journal_issn": "1474-5488",
"pub_date": "2025-05-18", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-L1", "研究类型::RCT::3期", "场景::新辅助", "终点::OS"]},
{"pmid": 39000115,
"title": "Amivantamab plus Lazertinib vs Osimertinib in EGFR-mutant NSCLC: MARIPOSA",
"abstract": "Ami+laz showed superior PFS vs osi in tx-naive EGFR-mutant NSCLC.",
"authors": [{"family": "Cho", "given": "BC"}, {"family": "Lu", "given": "S"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-05-15", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::EGFR", "靶点::MET", "治疗::靶向治疗::双特异性抗体", "研究类型::RCT::3期", "场景::一线"]},
{"pmid": 39000116,
"title": "Sacituzumab Govitecan vs Docetaxel in HR+/HER2- mBC: TROPiCS-02 Final OS",
"abstract": "Trop-2 ADC improved OS in endocrine-resistant, chemotherapy-treated HR+/HER2- mBC.",
"authors": [{"family": "Rugo", "given": "HS"}, {"family": "Bardia", "given": "A"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2025-05-12", "pub_year": 2025,
"tag_paths": ["癌种::乳腺癌::HR阳性", "治疗::靶向治疗::ADC", "研究类型::RCT::3期", "终点::OS", "场景::二线"]},
{"pmid": 39000117,
"title": "Nivo+Ipi vs Chemo in dMMR/MSI-H mCRC: CheckMate 8HW",
"abstract": "Dual immunotherapy significantly improved PFS vs chemo in dMMR/MSI-H mCRC.",
"authors": [{"family": "Lenz", "given": "HJ"}, {"family": "Van Cutsem", "given": "E"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-05-08", "pub_year": 2025,
"tag_paths": ["癌种::结直肠癌", "靶点::MSI", "治疗::免疫治疗::PD-1", "治疗::免疫治疗::CTLA-4", "研究类型::RCT::3期", "场景::一线"]},
{"pmid": 39000118,
"title": "SABR vs Standard RT in Oligometastatic NSCLC: SABR-COMET-10",
"abstract": "SABR improved OS and PFS in pts with 4-10 oligometastatic NSCLC lesions.",
"authors": [{"family": "Palma", "given": "DA"}, {"family": "Olson", "given": "R"}],
"journal": "The Lancet", "journal_issn": "0140-6736",
"pub_date": "2025-05-05", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::放疗::SBRT", "场景::寡转移", "终点::OS"]},
{"pmid": 39000119,
"title": "Datopotamab Deruxtecan vs Docetaxel in Advanced NSCLC: TROPION-Lung01",
"abstract": "Dato-DXd showed numerically improved PFS and favorable safety vs docetaxel in pretreated NSCLC.",
"authors": [{"family": "Ahn", "given": "MJ"}, {"family": "Paz-Ares", "given": "L"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2025-05-01", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::靶向治疗::ADC", "研究类型::RCT::3期", "场景::二线", "终点::PFS"]},
{"pmid": 39000120,
"title": "NCCN Guidelines: NSCLC Version 5.2025",
"abstract": "Updated NCCN guidelines for NSCLC: osimertinib+chemo category 1; amivantamab+lazertinib added.",
"authors": [{"family": "Ettinger", "given": "DS"}, {"family": "Wood", "given": "DE"}],
"journal": "Journal of the NCCN", "journal_issn": "1540-1405",
"pub_date": "2025-05-01", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "研究类型::指南", "场景::一线"]},
{"pmid": 39000121,
"title": "Fruquintinib plus Paclitaxel in Advanced Gastric Cancer: FRUTIGA",
"abstract": "Fruquintinib plus paclitaxel significantly improved PFS in pretreated advanced GC/GEJC.",
"authors": [{"family": "Wang", "given": "FH"}, {"family": "Shen", "given": "L"}],
"journal": "Annals of Oncology", "journal_issn": "0923-7534",
"pub_date": "2025-04-28", "pub_year": 2025,
"tag_paths": ["癌种::胃癌", "治疗::抗血管生成", "研究类型::RCT::3期", "场景::二线", "终点::PFS"]},
{"pmid": 39000122,
"title": "Long-Term Follow-up of CAR-T in r/r ALL: ELIANA 5-Year",
"abstract": "Tisagenlecleucel showed durable remissions with 55% 5-year EFS in pediatric/young adult r/r B-ALL.",
"authors": [{"family": "Maude", "given": "SL"}, {"family": "Laetsch", "given": "TW"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-04-25", "pub_year": 2025,
"tag_paths": ["癌种::血液肿瘤::白血病", "治疗::免疫治疗::CAR-T", "终点::OS", "终点::生物标志物"]},
{"pmid": 39000123,
"title": "Neoadjuvant Pembrolizumab+Chemotherapy in Early TNBC: KEYNOTE-522 Final",
"abstract": "Pembro neoadjuvant/adjuvant in TNBC confirmed sustained EFS and OS benefit at 5 years.",
"authors": [{"family": "Schmid", "given": "P"}, {"family": "Cortes", "given": "J"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-04-22", "pub_year": 2025,
"tag_paths": ["癌种::乳腺癌::三阴性乳腺癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::新辅助", "终点::OS"]},
{"pmid": 39000124,
"title": "Lenvatinib plus Pembrolizumab vs Sunitinib in aRCC: CLEAR 5Y",
"abstract": "Lenva+pembro maintained OS and PFS advantage over sunitinib in 1L aRCC at 5 years.",
"authors": [{"family": "Motzer", "given": "RJ"}, {"family": "Porta", "given": "C"}],
"journal": "Lancet Oncology", "journal_issn": "1474-5488",
"pub_date": "2025-04-18", "pub_year": 2025,
"tag_paths": ["癌种::肾癌", "治疗::靶向治疗::TKI", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000125,
"title": "Brigatinib vs Crizotinib in ALK+ NSCLC: ALTA-1L Final OS",
"abstract": "Brigatinib showed OS trend favoring vs crizotinib with reduced CNS progression.",
"authors": [{"family": "Camidge", "given": "DR"}, {"family": "Kim", "given": "HR"}],
"journal": "Journal of Thoracic Oncology", "journal_issn": "1556-0864",
"pub_date": "2025-04-15", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ALK", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "终点::OS"]},
{"pmid": 39000126,
"title": "Systematic Review: PD-1/PD-L1 Inhibitors in MSI-H Solid Tumors",
"abstract": "Meta-analysis of 45 trials: PD-1/PD-L1 inhibitors 38% pooled ORR across MSI-H tumors.",
"authors": [{"family": "Andre", "given": "T"}, {"family": "Cohen", "given": "R"}],
"journal": "Cancer Discovery", "journal_issn": "2159-8290",
"pub_date": "2025-04-12", "pub_year": 2025,
"tag_paths": ["靶点::MSI", "治疗::免疫治疗::PD-1", "治疗::免疫治疗::PD-L1", "研究类型::Meta分析", "终点::ORR"]},
{"pmid": 39000127,
"title": "Tucatinib+Trastuzumab+Capecitabine in HER2+ mBC with Brain Mets: HER2CLIMB-02",
"abstract": "Tucatinib-based triplet improved intracranial PFS and OS in HER2+ BC with brain mets.",
"authors": [{"family": "Lin", "given": "NU"}, {"family": "Murthy", "given": "RK"}],
"journal": "JAMA Oncology", "journal_issn": "2374-2437",
"pub_date": "2025-04-08", "pub_year": 2025,
"tag_paths": ["癌种::乳腺癌::HER2阳性", "靶点::HER2", "治疗::靶向治疗::TKI", "研究类型::RCT::2期", "终点::OS"]},
{"pmid": 39000128,
"title": "Maintenance Olaparib in gBRCA-Mutated mPC: POLO Final OS",
"abstract": "Olaparib maintenance showed OS numerical improvement in gBRCA-mutated metastatic pancreatic cancer.",
"authors": [{"family": "Golan", "given": "T"}, {"family": "Hammel", "given": "P"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2025-04-05", "pub_year": 2025,
"tag_paths": ["癌种::胰腺癌", "靶点::BRCA", "治疗::靶向治疗", "研究类型::RCT::3期", "场景::维持", "终点::OS"]},
{"pmid": 39000129,
"title": "AI-Based Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer",
"abstract": "Deep learning on H&E slides predicted pCR AUC 0.92 in external validation across 3 cohorts.",
"authors": [{"family": "Sammut", "given": "SJ"}, {"family": "Crispin-Ortuzar", "given": "M"}],
"journal": "Nature Medicine", "journal_issn": "1078-8956",
"pub_date": "2025-04-02", "pub_year": 2025,
"tag_paths": ["癌种::乳腺癌", "场景::新辅助", "治疗::化疗", "终点::生物标志物", "研究类型::转化研究"]},
{"pmid": 39000130,
"title": "Repotrectinib in ROS1-Positive Advanced NSCLC: TRIDENT-1 Updated",
"abstract": "Repotrectinib showed durable responses in TKI-naive and pretreated ROS1+ NSCLC, including CNS.",
"authors": [{"family": "Drilon", "given": "A"}, {"family": "Cho", "given": "BC"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-03-30", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ROS1", "治疗::靶向治疗::TKI", "终点::ORR", "终点::PFS"]},
{"pmid": 39000131,
"title": "Zanidatamab in Previously Treated HER2+ Biliary Tract Cancer: HERIZON-BTC-01",
"abstract": "HER2 bispecific Ab showed meaningful ORR and durable responses in HER2+ BTC.",
"authors": [{"family": "Harding", "given": "JJ"}, {"family": "Piha-Paul", "given": "S"}],
"journal": "Lancet Oncology", "journal_issn": "1474-5488",
"pub_date": "2025-03-27", "pub_year": 2025,
"tag_paths": ["靶点::HER2", "治疗::靶向治疗::双特异性抗体", "研究类型::RCT::2期", "终点::ORR"]},
{"pmid": 39000132,
"title": "Ivosidenib plus Azacitidine in IDH1-Mutant AML: AGILE Final",
"abstract": "IDH1 inhibitor plus AZA showed OS improvement in newly diagnosed IDH1-mutant AML.",
"authors": [{"family": "Montesinos", "given": "P"}, {"family": "Recher", "given": "C"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-03-25", "pub_year": 2025,
"tag_paths": ["癌种::血液肿瘤::白血病", "靶点::IDH", "治疗::靶向治疗", "研究类型::RCT::3期", "终点::OS"]},
{"pmid": 39000133,
"title": "Pembro in BCG-Unresponsive NMIBC: KEYNOTE-057 Final",
"abstract": "Pembro showed durable CR in high-risk NMIBC. 36-month CR rate: 22%.",
"authors": [{"family": "Balar", "given": "AV"}, {"family": "Kamat", "given": "AM"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2025-03-22", "pub_year": 2025,
"tag_paths": ["癌种::膀胱癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::2期", "终点::ORR"]},
{"pmid": 39000134,
"title": "Liquid Biopsy for MRD Detection in CRC: GALAXY Study",
"abstract": "ctDNA-based MRD detection post-surgery strongly predicted recurrence in stage II-III CRC (HR 11.3).",
"authors": [{"family": "Kotani", "given": "D"}, {"family": "Oki", "given": "E"}],
"journal": "Nature Medicine", "journal_issn": "1078-8956",
"pub_date": "2025-03-18", "pub_year": 2025,
"tag_paths": ["癌种::结直肠癌", "终点::生物标志物", "场景::辅助", "研究类型::转化研究"]},
{"pmid": 39000135,
"title": "Selpercatinib in RET Fusion-Positive Solid Tumors: LIBRETTO-001 Pan-Tumor",
"abstract": "RET inhibitor showed 44% ORR across RET fusion+ non-lung/non-thyroid solid tumors.",
"authors": [{"family": "Subbiah", "given": "V"}, {"family": "Wolf", "given": "J"}],
"journal": "Cancer Discovery", "journal_issn": "2159-8290",
"pub_date": "2025-03-15", "pub_year": 2025,
"tag_paths": ["靶点::RET", "治疗::靶向治疗::TKI", "终点::ORR"]},
{"pmid": 39000136,
"title": "First-Line Atezo/Bev in Advanced HCC: IMbrave150 5-Year OS",
"abstract": "Atezo/Bev maintained OS benefit at 5 years in advanced HCC (HR 0.66).",
"authors": [{"family": "Finn", "given": "RS"}, {"family": "Qin", "given": "S"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-03-12", "pub_year": 2025,
"tag_paths": ["癌种::肝癌::肝细胞癌", "治疗::免疫治疗::PD-L1", "治疗::抗血管生成", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000137,
"title": "Darolutamide + ADT vs ADT alone in mHSPC: ARASENS 5-Year",
"abstract": "Triplet therapy with darolutamide+ADT+docetaxel continued OS improvement vs ADT+docetaxel.",
"authors": [{"family": "Smith", "given": "MR"}, {"family": "Hussain", "given": "M"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-03-08", "pub_year": 2025,
"tag_paths": ["癌种::前列腺癌", "治疗::内分泌治疗", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000138,
"title": "Durvalumab+Tremelimumab in 1L HCC: HIMALAYA 4-Year OS",
"abstract": "STRIDE regimen showed sustained OS improvement. 4-year OS: 25.2% vs 18.5% with sorafenib.",
"authors": [{"family": "Abou-Alfa", "given": "GK"}, {"family": "Lau", "given": "G"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2025-03-05", "pub_year": 2025,
"tag_paths": ["癌种::肝癌::肝细胞癌", "治疗::免疫治疗::PD-L1", "治疗::免疫治疗::CTLA-4", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000139,
"title": "Adagrasib plus Cetuximab vs Chemotherapy in KRAS G12C mCRC: KRYSTAL-1",
"abstract": "Adagrasib+cetuximab improved ORR (34% vs 6%) and PFS vs standard in pretreated KRAS G12C mCRC.",
"authors": [{"family": "Yaeger", "given": "R"}, {"family": "Weiss", "given": "J"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-03-01", "pub_year": 2025,
"tag_paths": ["癌种::结直肠癌", "靶点::KRAS", "治疗::靶向治疗", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
{"pmid": 39000140,
"title": "Real-World PD-1 Inhibitors in Chinese Patients with Advanced NSCLC",
"abstract": "In 8,423 real-world patients, PD-1 inhibitors median OS 18.5mo vs 12.1mo with chemo alone.",
"authors": [{"family": "Wu", "given": "YL"}, {"family": "Zhou", "given": "Q"}],
"journal": "Clinical Cancer Research", "journal_issn": "1078-0432",
"pub_date": "2025-02-28", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-1", "研究类型::真实世界", "终点::OS"]},
{"pmid": 39000141,
"title": "ESMO Guidelines: HCC Diagnosis, Treatment and Follow-up",
"abstract": "Updated ESMO guidelines: 1L atezo+bev or durva+treme; 2L options expanded.",
"authors": [{"family": "Vogel", "given": "A"}, {"family": "Cervantes", "given": "A"}],
"journal": "Annals of Oncology", "journal_issn": "0923-7534",
"pub_date": "2025-02-25", "pub_year": 2025,
"tag_paths": ["癌种::肝癌::肝细胞癌", "研究类型::指南", "场景::一线", "场景::二线"]},
{"pmid": 39000142,
"title": "Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma: AMBASSADOR",
"abstract": "Adjuvant pembro improved DFS vs observation in high-risk MIUC after radical surgery.",
"authors": [{"family": "Apolo", "given": "AB"}, {"family": "Ballman", "given": "KV"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-02-22", "pub_year": 2025,
"tag_paths": ["癌种::膀胱癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::辅助"]},
{"pmid": 39000143,
"title": "Tepotinib in MET Exon 14 Skipping NSCLC: VISION Final",
"abstract": "MET inhibitor tepotinib showed durable responses in METex14 NSCLC across lines, including elderly.",
"authors": [{"family": "Paik", "given": "PK"}, {"family": "Felip", "given": "E"}],
"journal": "JAMA Oncology", "journal_issn": "2374-2437",
"pub_date": "2025-02-18", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::MET", "治疗::靶向治疗::TKI", "研究类型::RCT::2期", "终点::ORR"]},
{"pmid": 39000144,
"title": "Neoadjuvant Nivolumab+Chemo in Resectable Gastric Cancer: DANTE",
"abstract": "Adding nivo to FLOT improved pCR rate in resectable GC.",
"authors": [{"family": "Al-Batran", "given": "SE"}, {"family": "Lorenzen", "given": "S"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2025-02-15", "pub_year": 2025,
"tag_paths": ["癌种::胃癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::2期", "场景::新辅助", "终点::ORR"]},
{"pmid": 39000145,
"title": "Lorlatinib vs Crizotinib in 1L ALK+ Advanced NSCLC: CROWN 5-Year PFS",
"abstract": "Lorlatinib showed unprecedented 5-year PFS of 60% vs 8% with crizotinib in ALK+ NSCLC.",
"authors": [{"family": "Solomon", "given": "BJ"}, {"family": "Bauer", "given": "TM"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2025-02-10", "pub_year": 2025,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ALK", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
{"pmid": 39000146,
"title": "Mutation-Targeted Neoadjuvant Therapy in Pancreatic Cancer",
"abstract": "Germline/somatic mutation-guided neoadjuvant therapy improved R0 resection rate in LAPC (62% vs 35%).",
"authors": [{"family": "O'Reilly", "given": "EM"}, {"family": "Yu", "given": "KH"}],
"journal": "Clinical Cancer Research", "journal_issn": "1078-0432",
"pub_date": "2025-02-05", "pub_year": 2025,
"tag_paths": ["癌种::胰腺癌", "靶点::BRCA", "治疗::靶向治疗", "场景::新辅助", "研究类型::真实世界"]},
{"pmid": 39000147,
"title": "Pembro in Advanced Endometrial Cancer: KEYNOTE-775 Biomarker Analysis",
"abstract": "PD-L1 CPS and TMB independently predicted response to pembro+lenvatinib in EC.",
"authors": [{"family": "Makker", "given": "V"}, {"family": "Colombo", "given": "N"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2025-02-01", "pub_year": 2025,
"tag_paths": ["癌种::妇科肿瘤::子宫内膜癌", "靶点::TMB", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "终点::生物标志物"]},
{"pmid": 39000148,
"title": "AI-Assisted Colonoscopy for CRC Screening: Meta-Analysis of 21 RCTs",
"abstract": "AI-assisted colonoscopy increased ADR by 24% and reduced miss rate by 50%.",
"authors": [{"family": "Hassan", "given": "C"}, {"family": "Spadaccini", "given": "M"}],
"journal": "The Lancet", "journal_issn": "0140-6736",
"pub_date": "2025-01-28", "pub_year": 2025,
"tag_paths": ["癌种::结直肠癌", "研究类型::Meta分析", "终点::生物标志物"]},
{"pmid": 39000149,
"title": "Bemarituzumab plus mFOLFOX6 in FGFR2b GC: FIGHT Final",
"abstract": "FGFR2b-targeted antibody plus chemo improved OS in FGFR2b-overexpressing GC.",
"authors": [{"family": "Wainberg", "given": "ZA"}, {"family": "Enzinger", "given": "PC"}],
"journal": "JAMA Oncology", "journal_issn": "2374-2437",
"pub_date": "2025-01-25", "pub_year": 2025,
"tag_paths": ["癌种::胃癌", "靶点::FGFR", "治疗::靶向治疗", "研究类型::RCT::3期", "终点::OS"]},
{"pmid": 39000150,
"title": "mRNA-4157 (V940) plus Pembrolizumab in High-Risk Melanoma: KEYNOTE-942",
"abstract": "Personalized mRNA vaccine plus pembro reduced recurrence risk by 49% vs pembro alone in resected melanoma.",
"authors": [{"family": "Weber", "given": "JS"}, {"family": "Carlino", "given": "MS"}],
"journal": "The Lancet", "journal_issn": "0140-6736",
"pub_date": "2025-01-20", "pub_year": 2025,
"tag_paths": ["癌种::黑色素瘤", "治疗::免疫治疗::PD-1", "研究类型::RCT::2期", "场景::辅助", "终点::PFS"]},
# ── 近日文献（用于首页测试） ──
{"pmid": 39000201,
"title": "Alectinib in ALK-Positive Early-Stage NSCLC: ALINA Updated CNS Analysis",
"abstract": "Alectinib demonstrated superior CNS DFS vs chemo in resected ALK+ NSCLC, with 4-year CNS DFS 98%.",
"authors": [{"family": "Solomon", "given": "BJ", "affiliation": "Peter MacCallum Cancer Centre, Melbourne"}, {"family": "Wu", "given": "YL", "affiliation": "Guangdong Provincial People's Hospital"}, {"family": "John", "given": "T", "affiliation": "Austin Health"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"doi": "10.1056/NEJMoa2400381", "pmc_id": "PMC11223344", "is_oa": True, "cited_by_count": 24,
"pub_types": ["Journal Article", "Randomized Controlled Trial", "Clinical Trial, Phase III"],
"pub_date": "2026-07-06", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ALK", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::辅助", "终点::PFS"]},
{"pmid": 39000202,
"title": "Enfortumab Vedotin + Pembrolizumab in Untreated Advanced Urothelial Carcinoma: EV-302 Final OS",
"abstract": "EV+pembro combination continued to show significant OS benefit over chemo in 1L advanced UC at final analysis.",
"authors": [{"family": "Powles", "given": "T", "affiliation": "Barts Cancer Institute, London"}, {"family": "Rosenberg", "given": "JE", "affiliation": "Memorial Sloan Kettering"}, {"family": "Sonpavde", "given": "GP", "affiliation": "AdventHealth Cancer Institute"}],
"journal": "JAMA Oncology", "journal_issn": "2374-2437",
"doi": "10.1001/jamaoncol.2024.1234", "cited_by_count": 18,
"pub_types": ["Journal Article", "Randomized Controlled Trial", "Clinical Trial, Phase III"],
"pub_date": "2026-07-06", "pub_year": 2026,
"tag_paths": ["癌种::膀胱癌", "治疗::靶向治疗::ADC", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000203,
"title": "Trastuzumab Deruxtecan in HER2-Mutant Advanced NSCLC: DESTINY-Lung02 5-Year Update",
"abstract": "T-DXd continued to show durable responses in HER2-mutant NSCLC with median DoR 18.6 months.",
"authors": [{"family": "Li", "given": "BT", "affiliation": "Memorial Sloan Kettering Cancer Center"}, {"family": "Smit", "given": "EF", "affiliation": "Netherlands Cancer Institute"}, {"family": "Goto", "given": "Y", "affiliation": "National Cancer Center Hospital, Tokyo"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"doi": "10.1200/JCO.24.00123",
"pub_types": ["Journal Article", "Clinical Trial, Phase II"],
"pub_date": "2026-07-05", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::HER2", "治疗::靶向治疗::ADC", "研究类型::RCT::2期", "终点::ORR"]},
{"pmid": 39000204,
"title": "Pembrolizumab plus Chemoradiotherapy in Locally Advanced Cervical Cancer: KEYNOTE-A18 Updated",
"abstract": "Pembro plus chemoradiotherapy improved PFS in locally advanced cervical cancer, benefit consistent across subgroups.",
"authors": [{"family": "Lorusso", "given": "D", "affiliation": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milan"}, {"family": "Colombo", "given": "N", "affiliation": "University of Milan"}, {"family": "Tewari", "given": "KS", "affiliation": "University of California, Irvine"}],
"journal": "The Lancet", "journal_issn": "0140-6736",
"doi": "10.1016/S0140-6736(24)01568-2", "cited_by_count": 42,
"pub_types": ["Journal Article", "Randomized Controlled Trial", "Clinical Trial, Phase III"],
"pub_date": "2026-07-05", "pub_year": 2026,
"tag_paths": ["癌种::妇科肿瘤::宫颈癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
{"pmid": 39000205,
"title": "Lorlatinib in ALK-Positive Advanced NSCLC: CROWN 6-Year PFS Analysis",
"abstract": "Updated CROWN analysis: lorlatinib showed 62% 6-year PFS in 1L ALK+ NSCLC, with sustained CNS protection.",
"authors": [{"family": "Solomon", "given": "BJ", "affiliation": "Peter MacCallum Cancer Centre"}, {"family": "Bauer", "given": "TM", "affiliation": "Sarah Cannon Research Institute"}, {"family": "Mok", "given": "TS", "affiliation": "The Chinese University of Hong Kong"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"doi": "10.1056/NEJMoa2405681", "pmc_id": "PMC11223345", "is_oa": True, "cited_by_count": 56,
"pub_types": ["Journal Article", "Randomized Controlled Trial", "Clinical Trial, Phase III"],
"pub_date": "2026-07-04", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ALK", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
{"pmid": 39000206,
"title": "Belantamab Mafodotin + Pomalidomide + Dex in Relapsed/Refractory MM: DREAMM-8",
"abstract": "Belantamab mafodotin triplet significantly improved PFS vs pomalidomide+dex in RRMM, HR 0.52.",
"authors": [{"family": "Dimopoulos", "given": "MA"}, {"family": "Beksac", "given": "M"}, {"family": "Pour", "given": "L"}],
"journal": "Blood", "journal_issn": "0006-4971",
"doi": "10.1182/blood.2024026481",
"pub_date": "2026-07-03", "pub_year": 2026,
"tag_paths": ["癌种::血液肿瘤::多发性骨髓瘤", "治疗::靶向治疗::ADC", "研究类型::RCT::3期", "场景::二线", "终点::PFS"]},
{"pmid": 39000207,
"title": "Neoadjuvant Nivolumab Relatlimab in Resectable Melanoma: RELATIVITY-098",
"abstract": "Neoadjuvant nivo+rela improved event-free survival vs surgery alone in resectable stage III melanoma.",
"authors": [{"family": "Long", "given": "GV"}, {"family": "Mandalà", "given": "M"}, {"family": "Lebbé", "given": "C"}],
"journal": "JAMA", "journal_issn": "0098-7484",
"doi": "10.1001/jama.2024.12345",
"pub_date": "2026-07-03", "pub_year": 2026,
"tag_paths": ["癌种::黑色素瘤", "治疗::免疫治疗::PD-1", "治疗::免疫治疗::CTLA-4", "研究类型::RCT::3期", "场景::新辅助", "终点::PFS"]},
{"pmid": 39000208,
"title": "FOLFIRINOX versus Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer: NAPOLEON-3",
"abstract": "Modified FOLFIRINOX showed numerically superior OS vs gem+nap in mPC; tolerability favored the control arm.",
"authors": [{"family": "Conroy", "given": "T"}, {"family": "Desseigne", "given": "F"}, {"family": "Ychou", "given": "M"}],
"journal": "The Lancet Oncology", "journal_issn": "1474-5488",
"doi": "10.1016/S1470-2045(24)00567-1",
"pub_date": "2026-07-01", "pub_year": 2026,
"tag_paths": ["癌种::胰腺癌", "治疗::化疗", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000209,
"title": "Sotorasib + Panitumumab vs Chemo in KRAS G12C mCRC: CodeBreaK 300 Final OS",
"abstract": "Sotorasib+panitumumab maintained OS benefit vs standard in chemorefractory KRAS G12C mCRC.",
"authors": [{"family": "Fakih", "given": "MG"}, {"family": "Kopetz", "given": "S"}, {"family": "Kim", "given": "TW"}],
"journal": "Annals of Oncology", "journal_issn": "0923-7534",
"doi": "10.1016/j.annonc.2024.06.012",
"pub_date": "2026-06-30", "pub_year": 2026,
"tag_paths": ["癌种::结直肠癌", "靶点::KRAS", "治疗::靶向治疗", "研究类型::RCT::3期", "场景::二线", "终点::OS"]},
{"pmid": 39000210,
"title": "Zanidatamab in Previously Treated HER2+ Colorectal Cancer: Phase 2 Update",
"abstract": "Zanidatamab, a HER2 bispecific antibody, showed promising ORR of 38% in pretreated HER2+ mCRC.",
"authors": [{"family": "Siena", "given": "S"}, {"family": "Sartore-Bianchi", "given": "A"}, {"family": "Marsh", "given": "S"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"doi": "10.1200/JCO.24.00987",
"pub_date": "2026-06-30", "pub_year": 2026,
"tag_paths": ["癌种::结直肠癌", "靶点::HER2", "治疗::靶向治疗::双特异性抗体", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
# ── 更多测试数据（用于翻页测试） ──
{"pmid": 39000301,
"title": "Tislelizumab plus Chemotherapy in Advanced NSCLC: RATIONALE-307 5-Year Update",
"abstract": "Long-term follow-up confirms OS benefit of tislelizumab+chemo in 1L advanced squamous NSCLC.",
"authors": [{"family": "Wang", "given": "J"}, {"family": "Zhou", "given": "C"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2026-06-25", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000302,
"title": "Sintilimab plus Chemo vs Chemo in Advanced ESCC: ORIENT-15 Final OS",
"abstract": "Sintilimab plus chemo showed sustained OS benefit in advanced ESCC across PD-L1 subgroups.",
"authors": [{"family": "Xu", "given": "RH"}, {"family": "Song", "given": "Y"}],
"journal": "BMJ", "journal_issn": "0959-8138",
"pub_date": "2026-06-22", "pub_year": 2026,
"tag_paths": ["癌种::食管癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000303,
"title": "Camrelizumab plus Rivoceranib in Advanced HCC: CARES-310 Updated",
"abstract": "Camrelizumab+rivoceranib maintained OS and PFS benefit in 1L advanced HCC; QoL analysis favorable.",
"authors": [{"family": "Qin", "given": "S"}, {"family": "Chan", "given": "SL"}],
"journal": "The Lancet", "journal_issn": "0140-6736",
"pub_date": "2026-06-20", "pub_year": 2026,
"tag_paths": ["癌种::肝癌::肝细胞癌", "治疗::免疫治疗::PD-1", "治疗::抗血管生成", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000304,
"title": "Serplulimab plus Chemo in ES-SCLC: ASTRUM-005 3-Year OS",
"abstract": "PD-1 inhibitor serplulimab+chemo showed sustained 3-year OS benefit in extensive-stage SCLC.",
"authors": [{"family": "Cheng", "given": "Y"}, {"family": "Han", "given": "L"}],
"journal": "JAMA", "journal_issn": "0098-7484",
"pub_date": "2026-06-18", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::小细胞肺癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000305,
"title": "Penpulimab plus Chemo in Advanced NSCLC: AK105-302",
"abstract": "Penpulimab plus carboplatin+paclitaxel improved PFS in 1L advanced squamous NSCLC.",
"authors": [{"family": "Ma", "given": "Z"}, {"family": "Zhang", "given": "L"}],
"journal": "Lung Cancer", "journal_issn": "0169-5002",
"pub_date": "2026-06-15", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
{"pmid": 39000306,
"title": "Surufatinib vs Placebo in Advanced Pancreatic Neuroendocrine Tumors: SANET-p",
"abstract": "Surufatinib improved PFS in advanced pancreatic NETs with manageable safety profile.",
"authors": [{"family": "Xu", "given": "J"}, {"family": "Shen", "given": "L"}],
"journal": "Clinical Cancer Research", "journal_issn": "1078-0432",
"pub_date": "2026-06-12", "pub_year": 2026,
"tag_paths": ["癌种::胰腺癌", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
{"pmid": 39000307,
"title": "Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: ADAURA 7-Year OS",
"abstract": "ADAURA 7-year OS update: adjuvant osimertinib HR 0.49 for OS in stage IB-IIIA EGFR-mutant NSCLC.",
"authors": [{"family": "Herbst", "given": "RS"}, {"family": "Wu", "given": "YL"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2026-06-10", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::EGFR", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::辅助", "终点::OS"]},
{"pmid": 39000308,
"title": "Talazoparib plus Enzalutamide in mCRPC: TALAPRO-2 Final OS",
"abstract": "PARP inhibitor talazoparib+enzalutamide OS benefit confirmed in HRR-mutated mCRPC.",
"authors": [{"family": "Agarwal", "given": "N"}, {"family": "Azad", "given": "AA"}],
"journal": "The Lancet", "journal_issn": "0140-6736",
"pub_date": "2026-06-08", "pub_year": 2026,
"tag_paths": ["癌种::前列腺癌", "靶点::BRCA", "治疗::靶向治疗::PARP抑制剂", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000309,
"title": "First-Line Nivolumab plus Ipilimumab in MSI-H mCRC: CheckMate 8HW 4-Year",
"abstract": "Nivo+ipi maintained PFS benefit at 4-year follow-up in MSI-H/dMMR mCRC, with high complete response rate.",
"authors": [{"family": "Lenz", "given": "HJ"}, {"family": "Yoshino", "given": "T"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2026-06-05", "pub_year": 2026,
"tag_paths": ["癌种::结直肠癌", "靶点::MSI", "治疗::免疫治疗::PD-1", "治疗::免疫治疗::CTLA-4", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
{"pmid": 39000310,
"title": "Ribociclib plus Endocrine Therapy in Early HR+/HER2- BC: NATALEE Updated",
"abstract": "Ribociclib+NSA IDFS benefit across stage II-III HR+/HER2- early breast cancer.",
"authors": [{"family": "Slamon", "given": "DJ"}, {"family": "Fasching", "given": "PA"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2026-06-02", "pub_year": 2026,
"tag_paths": ["癌种::乳腺癌::HR阳性", "靶点::PIK3CA", "治疗::靶向治疗::CDK4/6抑制剂", "研究类型::RCT::3期", "场景::辅助", "终点::PFS"]},
{"pmid": 39000311,
"title": "Pembrolizumab plus Lenvatinib in Advanced Endometrial Cancer: KEYNOTE-775 Final OS",
"abstract": "Pembro+lenva OS benefit sustained in pMMR advanced EC at final analysis.",
"authors": [{"family": "Makker", "given": "V"}, {"family": "Aghajanian", "given": "C"}],
"journal": "JAMA Oncology", "journal_issn": "2374-2437",
"pub_date": "2026-05-30", "pub_year": 2026,
"tag_paths": ["癌种::妇科肿瘤::子宫内膜癌", "治疗::靶向治疗::TKI", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000312,
"title": "Anti-PD-1 in Nasopharyngeal Carcinoma: JUPITER-02 5-Year OS",
"abstract": "Toripalimab+chemo 5-year OS rate 52% vs 33% with chemo alone in recurrent/metastatic NPC.",
"authors": [{"family": "Mai", "given": "HQ"}, {"family": "Chen", "given": "QY"}],
"journal": "Nature Medicine", "journal_issn": "1078-8956",
"pub_date": "2026-05-28", "pub_year": 2026,
"tag_paths": ["癌种::头颈肿瘤::鼻咽癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000313,
"title": "Crizotinib vs Chemo in ALK+ NSCLC: PROFILE 1029 10-Year Follow-Up",
"abstract": "10-year follow-up of crizotinib in Asian ALK+ NSCLC: median OS 52.3mo vs 38.5mo for chemo.",
"authors": [{"family": "Wu", "given": "YL"}, {"family": "Lu", "given": "S"}],
"journal": "Journal of Thoracic Oncology", "journal_issn": "1556-0864",
"pub_date": "2026-05-25", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ALK", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000314,
"title": "Avapritinib in Advanced GIST: NAVIGATOR 5-Year Update",
"abstract": "Long-term avapritinib shows durable responses in PDGFRA D842V-mutant and KIT-mutant GIST.",
"authors": [{"family": "Heinrich", "given": "MC"}, {"family": "Jones", "given": "RL"}],
"journal": "Clinical Cancer Research", "journal_issn": "1078-0432",
"pub_date": "2026-05-22", "pub_year": 2026,
"tag_paths": ["癌种::消化道肿瘤::GIST", "靶点::KIT", "治疗::靶向治疗::TKI", "研究类型::RCT::2期", "终点::ORR"]},
{"pmid": 39000315,
"title": "Vismodegib in Basal Cell Carcinoma: 8-Year Follow-Up",
"abstract": "Longest follow-up of hedgehog inhibitor in advanced BCC: median DoR 26.2 months, 5-year OS 48%.",
"authors": [{"family": "Sekulic", "given": "A"}, {"family": "Migden", "given": "MR"}],
"journal": "Cancer Discovery", "journal_issn": "2159-8290",
"pub_date": "2026-05-20", "pub_year": 2026,
"tag_paths": ["癌种::皮肤肿瘤", "靶点::Hedgehog", "治疗::靶向治疗", "研究类型::单臂", "终点::OS"]},
{"pmid": 39000316,
"title": "Nivolumab in Relapsed Malignant Mesothelioma: CONFIRM 3-Year OS",
"abstract": "Nivo improved OS in relapsed mesothelioma; benefit seen in both epithelioid and non-epithelioid subtypes.",
"authors": [{"family": "Fennell", "given": "DA"}, {"family": "Porter", "given": "C"}],
"journal": "The Lancet", "journal_issn": "0140-6736",
"pub_date": "2026-05-18", "pub_year": 2026,
"tag_paths": ["癌种::间皮瘤", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::二线", "终点::OS"]},
{"pmid": 39000317,
"title": "Pomalidomide and Daratumumab in RRMM: Updated Real-World Evidence",
"abstract": "Real-world study of 1200+ RRMM patients: pomalidomide+daratumumab triplet ORR 71%, median PFS 16.4mo.",
"authors": [{"family": "Richardson", "given": "PG"}, {"family": "Bahlis", "given": "NJ"}],
"journal": "Blood", "journal_issn": "0006-4971",
"pub_date": "2026-05-15", "pub_year": 2026,
"tag_paths": ["癌种::血液肿瘤::多发性骨髓瘤", "治疗::靶向治疗", "治疗::免疫治疗", "研究类型::真实世界", "场景::二线", "终点::PFS"]},
{"pmid": 39000318,
"title": "ESMO Guidelines: Management of Metastatic Colorectal Cancer 2026",
"abstract": "Updated ESMO mCRC guidelines: immunotherapy priority in MSI-H; RAS/BRAF testing expanded; TAS-102+bev new standard.",
"authors": [{"family": "Cervantes", "given": "A"}, {"family": "Van Cutsem", "given": "E"}],
"journal": "Annals of Oncology", "journal_issn": "0923-7534",
"pub_date": "2026-05-12", "pub_year": 2026,
"tag_paths": ["癌种::结直肠癌", "研究类型::指南", "场景::一线", "场景::二线", "终点::OS"]},
{"pmid": 39000319,
"title": "Lurbinectedin + Doxorubicin in Relapsed SCLC: Phase 2 Basket Trial",
"abstract": "Lurbinectedin+doxorubicin ORR 42% in relapsed SCLC, including chemo-resistant patients.",
"authors": [{"family": "Paz-Ares", "given": "L"}, {"family": "Trigo", "given": "JM"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2026-05-10", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::小细胞肺癌", "治疗::化疗", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
{"pmid": 39000320,
"title": "Trastuzumab Deruxtecan in HER2-Low Biliary Tract Cancer: Phase 2",
"abstract": "T-DXd demonstrated ORR of 32% in previously treated HER2-low BTC, with median DoR 11.3mo.",
"authors": [{"family": "Oh", "given": "DY"}, {"family": "Lee", "given": "CK"}],
"journal": "Lancet Oncology", "journal_issn": "1474-5488",
"pub_date": "2026-05-08", "pub_year": 2026,
"tag_paths": ["癌种::胆管癌", "靶点::HER2", "治疗::靶向治疗::ADC", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
{"pmid": 39000321,
"title": "Nivolumab plus Ipilimumab in Advanced HCC: CheckMate 9DW 5-Year",
"abstract": "Nivo+ipi sustained OS benefit vs lenva/sorafenib in 1L advanced HCC at 5-year landmark analysis.",
"authors": [{"family": "Yau", "given": "T"}, {"family": "Kudo", "given": "M"}],
"journal": "JAMA Oncology", "journal_issn": "2374-2437",
"pub_date": "2026-05-05", "pub_year": 2026,
"tag_paths": ["癌种::肝癌::肝细胞癌", "治疗::免疫治疗::PD-1", "治疗::免疫治疗::CTLA-4", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000322,
"title": "Entrectinib in NTRK Fusion-Positive Solid Tumors: Integrated Analysis",
"abstract": "Entrectinib showed 57% ORR across 14 tumor types with NTRK fusions; CNS ORR 50%.",
"authors": [{"family": "Doebele", "given": "RC"}, {"family": "Drilon", "given": "A"}],
"journal": "Cancer Discovery", "journal_issn": "2159-8290",
"pub_date": "2026-05-02", "pub_year": 2026,
"tag_paths": ["靶点::NTRK", "治疗::靶向治疗::TKI", "终点::ORR"]},
{"pmid": 39000323,
"title": "Ipatasertib plus Paclitaxel in PIK3CA-Mutant Breast Cancer: IPATunity130",
"abstract": "AKT inhibitor ipatasertib+chemo improved PFS in PIK3CA-mutant advanced TNBC.",
"authors": [{"family": "Schmid", "given": "P"}, {"family": "Cortes", "given": "J"}],
"journal": "Nature Medicine", "journal_issn": "1078-8956",
"pub_date": "2026-04-30", "pub_year": 2026,
"tag_paths": ["癌种::乳腺癌::三阴性乳腺癌", "靶点::PIK3CA", "治疗::靶向治疗", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
{"pmid": 39000324,
"title": "Claudin18.2-Targeted CAR-T in Advanced GI Cancers: Phase 1 Update",
"abstract": "CLDN18.2 CAR-T cell therapy showed 48% ORR in advanced gastric and pancreatic cancers.",
"authors": [{"family": "Qi", "given": "C"}, {"family": "Gong", "given": "J"}],
"journal": "Nature Medicine", "journal_issn": "1078-8956",
"pub_date": "2026-04-28", "pub_year": 2026,
"tag_paths": ["癌种::胃癌", "靶点::CLDN18.2", "治疗::免疫治疗::CAR-T", "研究类型::RCT::1期", "场景::二线", "终点::ORR"]},
{"pmid": 39000325,
"title": "Bispecific Antibodies in Multiple Myeloma: Systematic Review and Meta-Analysis",
"abstract": "Meta-analysis of 24 trials: BCMA bispecifics pooled ORR 63% in RRMM; CRS rate 55% mostly grade 1-2.",
"authors": [{"family": "Anderson", "given": "KC"}, {"family": "Munshi", "given": "NC"}],
"journal": "Blood", "journal_issn": "0006-4971",
"pub_date": "2026-04-25", "pub_year": 2026,
"tag_paths": ["癌种::血液肿瘤::多发性骨髓瘤", "靶点::BCMA", "治疗::免疫治疗::双特异性抗体", "研究类型::Meta分析", "终点::ORR"]},
{"pmid": 39000326,
"title": "Tucatinib in HER2+ CRC with Brain Metastases: MOUNTAINEER Update",
"abstract": "Tucatinib+trastuzumab showed intracranial ORR 29% in HER2+ mCRC with brain metastases.",
"authors": [{"family": "Strickler", "given": "JH"}, {"family": "Yoshino", "given": "T"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2026-04-22", "pub_year": 2026,
"tag_paths": ["癌种::结直肠癌", "靶点::HER2", "治疗::靶向治疗::TKI", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
{"pmid": 39000327,
"title": "Adjuvant Pembrolizumab in RCC: KEYNOTE-564 5-Year OS",
"abstract": "Adjuvant pembro in high-risk RCC: DFS benefit maintained at 5 years, OS trending favorable.",
"authors": [{"family": "Choueiri", "given": "TK"}, {"family": "Tomczak", "given": "P"}],
"journal": "The Lancet Oncology", "journal_issn": "1474-5488",
"pub_date": "2026-04-20", "pub_year": 2026,
"tag_paths": ["癌种::肾癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::辅助", "终点::OS"]},
{"pmid": 39000328,
"title": "Darolutamide plus ADT in High-Risk Biochemically Recurrent PC: ARAMIS 7-Year",
"abstract": "Darolutamide+ADT improved metastasis-free survival and OS in high-risk BCR at 7-year analysis.",
"authors": [{"family": "Fizazi", "given": "K"}, {"family": "Shore", "given": "N"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2026-04-18", "pub_year": 2026,
"tag_paths": ["癌种::前列腺癌", "治疗::内分泌治疗", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000329,
"title": "Osimertinib in Unresectable Stage III EGFR-Mutant NSCLC: LAURA Updated",
"abstract": "LAURA update: osimertinib PFS benefit confirmed in unresectable stage III EGFR-mutant NSCLC post-CRT.",
"authors": [{"family": "Lu", "given": "S"}, {"family": "Kato", "given": "T"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2026-04-15", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::EGFR", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::维持", "终点::PFS"]},
{"pmid": 39000330,
"title": "Mirvetuximab Soravtansine in FRα+ Ovarian Cancer: SORAYA 3-Year",
"abstract": "FRα-targeting ADC mirvetuximab maintained ORR of 32% in FRα-high platinum-resistant ovarian cancer.",
"authors": [{"family": "Matulonis", "given": "UA"}, {"family": "Oaknin", "given": "A"}],
"journal": "JAMA Oncology", "journal_issn": "2374-2437",
"pub_date": "2026-04-12", "pub_year": 2026,
"tag_paths": ["癌种::妇科肿瘤::卵巢癌", "靶点::FRα", "治疗::靶向治疗::ADC", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
{"pmid": 39000331,
"title": "Avelumab in Merkel Cell Carcinoma: JAVELIN Merkel 200 5-Year",
"abstract": "Avelumab 5-year OS rate 28% in mMCC; responses associated with PD-L1 expression and TMB.",
"authors": [{"family": "D'Angelo", "given": "SP"}, {"family": "Bhatia", "given": "S"}],
"journal": "Cancer Discovery", "journal_issn": "2159-8290",
"pub_date": "2026-04-10", "pub_year": 2026,
"tag_paths": ["癌种::皮肤肿瘤", "治疗::免疫治疗::PD-L1", "研究类型::RCT::2期", "终点::OS"]},
{"pmid": 39000332,
"title": "Zenocutuzumab in NRG1 Fusion-Positive Solid Tumors: Phase 2",
"abstract": "HER2/HER3 bispecific antibody showed ORR 34% across NRG1 fusion+ pancreatic, NSCLC, and other tumors.",
"authors": [{"family": "Schram", "given": "AM"}, {"family": "O'Reilly", "given": "EM"}],
"journal": "Cancer Discovery", "journal_issn": "2159-8290",
"pub_date": "2026-04-08", "pub_year": 2026,
"tag_paths": ["靶点::NRG1", "治疗::靶向治疗::双特异性抗体", "研究类型::RCT::2期", "终点::ORR"]},
{"pmid": 39000333,
"title": "Giredestrant vs Letrozole in ER+ Advanced Breast Cancer: acelERA",
"abstract": "Oral SERD giredestrant showed comparable PFS to letrozole in ER+/HER2- advanced BC with favorable safety.",
"authors": [{"family": "Martin", "given": "M"}, {"family": "Bardia", "given": "A"}],
"journal": "Annals of Oncology", "journal_issn": "0923-7534",
"pub_date": "2026-04-05", "pub_year": 2026,
"tag_paths": ["癌种::乳腺癌::HR阳性", "治疗::内分泌治疗", "研究类型::RCT::2期", "场景::一线", "终点::PFS"]},
{"pmid": 39000334,
"title": "Capecitabine Maintenance in Advanced Nasopharyngeal Carcinoma: Phase 3",
"abstract": "Capecitabine maintenance after chemo improved PFS in advanced NPC (median 18.5 vs 11.8 mo).",
"authors": [{"family": "Chen", "given": "YP"}, {"family": "Tang", "given": "LL"}],
"journal": "BMJ", "journal_issn": "0959-8138",
"pub_date": "2026-04-02", "pub_year": 2026,
"tag_paths": ["癌种::头颈肿瘤::鼻咽癌", "治疗::化疗", "研究类型::RCT::3期", "场景::维持", "终点::PFS"]},
{"pmid": 39000335,
"title": "Selinexor in KRAS-Mutant Advanced NSCLC: Phase 2 Study",
"abstract": "XPO1 inhibitor selinexor showed clinical activity in KRAS-mutant NSCLC, ORR 10%, DCR 58%.",
"authors": [{"family": "Skoulidis", "given": "F"}, {"family": "Govindan", "given": "R"}],
"journal": "Journal of Thoracic Oncology", "journal_issn": "1556-0864",
"pub_date": "2026-03-30", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::KRAS", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
{"pmid": 39000336,
"title": "Sacituzumab Govitecan in Advanced UC: TROPiCS-04 Final",
"abstract": "Trop-2 ADC sacituzumab govitecan showed OS benefit vs standard in platinum-refractory advanced UC.",
"authors": [{"family": "Tagawa", "given": "ST"}, {"family": "Balar", "given": "AV"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2026-03-28", "pub_year": 2026,
"tag_paths": ["癌种::膀胱癌", "治疗::靶向治疗::ADC", "研究类型::RCT::3期", "场景::二线", "终点::OS"]},
{"pmid": 39000337,
"title": "First-Line Atezolizumab in PD-L1+ NSCLC: IMPower110 5-Year",
"abstract": "Atezo monotherapy 5-year OS rate in PD-L1-high 1L NSCLC: 25% vs 17% with chemo.",
"authors": [{"family": "Herbst", "given": "RS"}, {"family": "Giaccone", "given": "G"}],
"journal": "JAMA Oncology", "journal_issn": "2374-2437",
"pub_date": "2026-03-25", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-L1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000338,
"title": "Targeted Therapy in NSCLC with Rare Driver Mutations: Chinese Real-World Study",
"abstract": "Real-world analysis of 3200+ NSCLC patients: 12% harbored rare drivers; targeted therapy improved outcomes over chemo.",
"authors": [{"family": "Zhou", "given": "Q"}, {"family": "Wu", "given": "YL"}],
"journal": "Clinical Cancer Research", "journal_issn": "1078-0432",
"pub_date": "2026-03-22", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::EGFR", "靶点::ALK", "靶点::ROS1", "研究类型::真实世界", "终点::OS"]},
{"pmid": 39000339,
"title": "TAS-102 plus Bevacizumab in Refractory mCRC: SUNLIGHT 3-Year",
"abstract": "TAS-102+bev maintained OS benefit at 3 years in chemorefractory mCRC; HR 0.61.",
"authors": [{"family": "Prager", "given": "GW"}, {"family": "Taieb", "given": "J"}],
"journal": "The Lancet Oncology", "journal_issn": "1474-5488",
"pub_date": "2026-03-20", "pub_year": 2026,
"tag_paths": ["癌种::结直肠癌", "治疗::化疗", "治疗::抗血管生成", "研究类型::RCT::3期", "场景::二线", "终点::OS"]},
{"pmid": 39000340,
"title": "Metastatic Castration-Sensitive Prostate Cancer: Treatment Intensification Patterns",
"abstract": "Real-world study of 4500+ mCSPC patients: triplet therapy adoption growing; ARAT+ADT+docetaxel improved outcomes.",
"authors": [{"family": "Ryan", "given": "CJ"}, {"family": "Agarwal", "given": "N"}],
"journal": "European Journal of Cancer", "journal_issn": "0959-8049",
"pub_date": "2026-03-18", "pub_year": 2026,
"tag_paths": ["癌种::前列腺癌", "治疗::内分泌治疗", "治疗::化疗", "研究类型::真实世界", "场景::一线", "终点::OS"]},
{"pmid": 39000341,
"title": "Tabelecleucel in EBV+ PTLD: Phase 3 ALLELE Trial",
"abstract": "EBV-specific T-cell therapy tabelecleucel improved OS in EBV+ post-transplant lymphoproliferative disease.",
"authors": [{"family": "Ptushkin", "given": "VN"}, {"family": "Nikiforow", "given": "S"}],
"journal": "Blood", "journal_issn": "0006-4971",
"pub_date": "2026-03-15", "pub_year": 2026,
"tag_paths": ["癌种::血液肿瘤::淋巴瘤", "治疗::免疫治疗", "研究类型::RCT::3期", "终点::OS"]},
{"pmid": 39000342,
"title": "Sotorasib in KRAS G12C NSCLC: CodeBreaK 100 5-Year Outcomes",
"abstract": "5-year pooled analysis of sotorasib in KRAS G12C NSCLC: median OS 12.5mo in pretreated patients.",
"authors": [{"family": "Janne", "given": "PA"}, {"family": "Riely", "given": "GJ"}],
"journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
"pub_date": "2026-03-12", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::KRAS", "治疗::靶向治疗", "研究类型::RCT::2期", "场景::二线", "终点::OS"]},
{"pmid": 39000343,
"title": "Ibrutinib in CLL: RESONATE-2 10-Year Follow-Up",
"abstract": "10-year follow-up: ibrutinib PFS rate 43% in 1L CLL; sustained OS benefit vs chlorambucil.",
"authors": [{"family": "Burger", "given": "JA"}, {"family": "Barr", "given": "PM"}],
"journal": "Blood", "journal_issn": "0006-4971",
"pub_date": "2026-03-10", "pub_year": 2026,
"tag_paths": ["癌种::血液肿瘤::白血病", "靶点::BTK", "治疗::靶向治疗::BTK抑制剂", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
{"pmid": 39000344,
"title": "Nivolumab in Advanced Squamous NSCLC: CheckMate 017 8-Year OS",
"abstract": "8-year OS rate with nivo in advanced squamous NSCLC: 12% vs 4% with docetaxel.",
"authors": [{"family": "Spigel", "given": "DR"}, {"family": "Brahmer", "given": "JR"}],
"journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
"pub_date": "2026-03-08", "pub_year": 2026,
"tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::二线", "终点::OS"]},
{"pmid": 39000345,
"title": "Adjuvant Encorafenib+Bini in BRAF-Mutant Stage III Melanoma: COLUMBUS 7-Year",
"abstract": "Adjuvant encorafenib+binimetinib sustained RFS benefit in BRAF V600-mutant stage III melanoma at 7 years.",
"authors": [{"family": "Robert", "given": "C"}, {"family": "Dummer", "given": "R"}],
"journal": "JAMA", "journal_issn": "0098-7484",
"pub_date": "2026-03-05", "pub_year": 2026,
"tag_paths": ["癌种::黑色素瘤", "靶点::BRAF", "治疗::靶向治疗", "研究类型::RCT::3期", "场景::辅助", "终点::PFS"]},
{"pmid": 39000346,
"title": "Pembrolizumab in MSI-H/dMMR CRC: KEYNOTE-177 5-Year Final",
"abstract": "Pembro 5-year PFS rate 34% vs 13% with chemo in 1L MSI-H/dMMR mCRC; OS HR 0.71.",
"authors": [{"family": "Andre", "given": "T"}, {"family": "Shiu", "given": "KK"}],
"journal": "The Lancet Oncology", "journal_issn": "1474-5488",
"pub_date": "2026-03-02", "pub_year": 2026,
"tag_paths": ["癌种::结直肠癌", "靶点::MSI", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
{"pmid": 39000347,
"title": "Zolbetuximab plus mFOLFOX6 in CLDN18.2+ GC: SPOTLIGHT Updated",
"abstract": "Zolbetuximab+chemo PFS and OS benefit confirmed in CLDN18.2+, HER2- advanced GC at updated analysis.",
"authors": [{"family": "Shah", "given": "MA"}, {"family": "Xu", "given": "RH"}],
"journal": "Nature Medicine", "journal_issn": "1078-8956",
"pub_date": "2026-02-28", "pub_year": 2026,
"tag_paths": ["癌种::胃癌", "靶点::CLDN18.2", "治疗::靶向治疗", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
{"pmid": 39000348,
"title": "T-DXd in HER2-Overexpressing Solid Tumors: DESTINY-PanTumor02",
"abstract": "T-DXd showed ORR 37% across HER2 IHC3+ solid tumors; median DoR 11.8 months in basket trial.",
"authors": [{"family": "Meric-Bernstam", "given": "F"}, {"family": "Hamilton", "given": "EP"}],
"journal": "Cancer Discovery", "journal_issn": "2159-8290",
"pub_date": "2026-02-25", "pub_year": 2026,
"tag_paths": ["靶点::HER2", "治疗::靶向治疗::ADC", "研究类型::RCT::2期", "终点::ORR"]},
{"pmid": 39000349,
"title": "Vosoritide in Achondroplasia: Phase 3 Final Results",
"abstract": "Vosoritide increased annualized growth velocity in children with achondroplasia; safety consistent with prior data.",
"authors": [{"family": "Savarirayan", "given": "R"}, {"family": "Tofts", "given": "L"}],
"journal": "The Lancet", "journal_issn": "0140-6736",
"pub_date": "2026-02-22", "pub_year": 2026,
"tag_paths": ["研究类型::RCT::3期", "终点::安全性"]},
{"pmid": 39000350,
"title": "CSCO Guidelines: Breast Cancer Treatment 2026",
"abstract": "Updated CSCO BC guidelines: CDK4/6 inhibitor adjuvant indication expanded; ADC in HER2-low updated recommendations.",
"authors": [{"family": "Jiang", "given": "ZF"}, {"family": "Li", "given": "JY"}],
"journal": "European Journal of Cancer", "journal_issn": "0959-8049",
"pub_date": "2026-02-20", "pub_year": 2026,
"tag_paths": ["癌种::乳腺癌", "研究类型::指南", "场景::一线", "场景::辅助"]},
]
async with async_session() as db:
lit_count, tag_count = 0, 0
for a in articles:
existing = await db.execute(select(GlobalLiterature.id).where(GlobalLiterature.pmid == a['pmid']))
if existing.scalar(): continue
lit = GlobalLiterature(id=uid(), pmid=a['pmid'], title=a['title'], abstract=a['abstract'],
authors=a['authors'], journal=a.get('journal'), journal_issn=a.get('journal_issn'),
doi=a.get('doi'), pub_date=d(a.get('pub_date')), pub_year=a.get('pub_year'),
pub_types=a.get('pub_types', []), mesh_headings=[], source="seed_data",
pmc_id=a.get('pmc_id'), is_oa=a.get('is_oa', False),
cited_by_count=a.get('cited_by_count', 0))
db.add(lit)
await db.flush()
lit_count += 1
# 关联标签
for path in a.get('tag_paths', []):
tag_id = tag_map.get(path)
if tag_id:
db.add(GlobalLiteratureTag(literature_id=lit.id, tag_id=tag_id, is_major=True))
tag_count += 1
await db.commit()
print(f" Literature: {lit_count} articles, {tag_count} tag associations")
async def main():
print("=== Seeding Data ===")
# 使用 Alembic 迁移建表（保证与生产 schema 一致）
import subprocess, sys
_backend = os.path.dirname(os.path.dirname(__file__))
_r = subprocess.run(
[sys.executable, "-m", "alembic", "-c", "alembic/alembic.ini", "upgrade", "head"],
cwd=_backend, capture_output=True, text=True,
)
if _r.returncode != 0:
print(" Alembic migration failed:", _r.stderr)
sys.exit(1)
print(" Tables migrated")
tag_map = await import_tags()
await import_journals()
await import_literature(tag_map)
# 创建 Demo 用户 + 订阅 + Feed
print(" Creating demo user...")
async with async_session() as db:
demo = User(id=uid(), email="demo@test.cn", hashed_password=hash_password("123456"),
display_name="王主任", title="主任医师")
db.add(demo)
tenant = Tenant(id=uid(), name="王主任的个人空间",
slug="demo-tenant", hospital_name="北京协和医院",
department_name="肿瘤内科", plan_type="team")
db.add(tenant)
await db.flush()
db.add(UserTenant(id=uid(), user_id=demo.id, tenant_id=tenant.id, role="owner", is_default=True))
await db.flush()
# 订阅主要癌种 + 治疗方式 + 研究类型（覆盖约 90% 的测试文献，确保翻页测试有足够 Feed）
for tag_path in [
"癌种::肺癌::非小细胞肺癌", "癌种::乳腺癌", "癌种::结直肠癌", "癌种::胃癌",
"癌种::肝癌::肝细胞癌", "癌种::食管癌", "癌种::胰腺癌", "癌种::前列腺癌",
"癌种::膀胱癌", "癌种::肾癌", "癌种::黑色素瘤", "癌种::血液肿瘤::多发性骨髓瘤",
"癌种::妇科肿瘤", "癌种::头颈癌",
"靶点::EGFR", "靶点::ALK", "靶点::KRAS", "靶点::HER2",
"治疗::免疫治疗::PD-1", "治疗::免疫治疗::PD-L1",
"治疗::靶向治疗::TKI", "治疗::靶向治疗::ADC",
"研究类型::RCT::3期", "研究类型::RCT::2期",
"终点::OS", "终点::PFS",
]:
tid = tag_map.get(tag_path)
if tid:
db.add(UserSubscription(id=uid(), user_id=demo.id, tenant_id=tenant.id,
tag_id=tid, match_mode="standard"))
await db.commit()
print(" Demo user: demo@test.cn / 123456 (订阅 26 个标签，覆盖主要癌种/治疗/研究类型)")
# 平台管理员（内置账号，无需注册）
admin = User(id=uid(), email="admin@scilit.cn", hashed_password=hash_password("admin123"),
display_name="平台管理员", platform_role="platform_owner")
db.add(admin)
print(" Platform admin: admin@scilit.cn / admin123 (platform_owner)")
# Demo activity data (saves, notes, reads)
lit_ids = (await db.execute(select(GlobalLiterature.id).limit(12))).scalars().all()
for i, lid in enumerate(lit_ids[:8]):
db.add(UserLiterature(id=uid(), user_id=demo.id, literature_id=lid, reading_status="completed" if i<5 else "reading", rating=4 if i<3 else (3 if i<6 else None)))
notes_text = ["联合方案OS获益显著，需权衡增加的毒性。对年轻、PS评分好的患者优先推荐。",
"入组标准严格，注意与真实世界的差异。结论可推广性需慎重。",
"T-DXd在HER2低表达中的突破，应重新审视我们的HER2检测报告阈值。",
"ctDNA指导辅助化疗的思路新颖，目前成本较高，普及尚需时日。"]
for i, lid in enumerate(lit_ids[:4]):
db.add(UserNote(id=uid(), user_id=demo.id, literature_id=lid, content=notes_text[i], is_private=(i%2==0)))
from app.models.interaction import UserFeed
for i, lid in enumerate(lit_ids[:10]):
feed = (await db.execute(select(UserFeed).where(UserFeed.user_id==demo.id, UserFeed.literature_id==lid))).scalar()
if feed: feed.is_read = (i<7); feed.read_at = datetime.now(UTC) if i<7 else None
await db.commit()
print(" Demo activity: 8 saves + 4 notes + 7 reads")
# Second tenant to make dashboards richer
t2 = Tenant(id=uid(), name="北京协和医院肿瘤内科", slug="pumch-onco", hospital_name="北京协和医院", department_name="肿瘤内科", is_personal=False)
db.add(t2)
u2 = User(id=uid(), email="zhang@pumch.cn", hashed_password=hash_password("123456"), display_name="张教授", title="科主任")
db.add(u2)
await db.flush()
db.add(UserTenant(id=uid(), user_id=u2.id, tenant_id=t2.id, role="owner", is_default=True))
await db.commit()
print(" Bonus: 2nd tenant + Zhang professor")
# 新药审批种子数据
lung_tag = tag_map.get("癌种::肺癌")
breast_tag = tag_map.get("癌种::乳腺癌")
liver_tag = tag_map.get("癌种::肝癌::肝细胞癌")
mm_tag = tag_map.get("癌种::血液肿瘤::多发性骨髓瘤")
gastric_tag = tag_map.get("癌种::胃癌")
melanoma_tag = tag_map.get("癌种::黑色素瘤")
drugs = [
("Tagrisso", "osimertinib", "EGFR", "EGFR突变晚期NSCLC一线+辅助", "FDA", "new_drug", date(2024,2,16), lung_tag, "NCT04035486", 39000101),
("Imfinzi", "durvalumab", "PD-L1", "不可切除III期NSCLC巩固治疗", "NMPA", "expanded_indication", date(2024,6,10), lung_tag, "NCT02125461", 39000114),
("Enhertu", "trastuzumab deruxtecan", "HER2", "HER2低表达转移性乳腺癌", "FDA", "new_drug", date(2024,8,5), breast_tag, "NCT04494425", 39000103),
("Trodelvy", "sacituzumab govitecan", "TROP2", "HR+/HER2-晚期乳腺癌", "FDA", "expanded_indication", date(2023,2,3), breast_tag, "NCT03901339", 39000116),
("Imdelltra", "tarlatamab", "DLL3/CD3", "广泛期SCLC后线治疗", "FDA", "new_drug", date(2024,5,16), lung_tag, "NCT05060016", None),
("Tecvayli", "teclistamab", "BCMA/CD3", "RRMM后线治疗", "FDA", "new_drug", date(2022,10,25), mm_tag, "NCT04557098", 39000110),
("Tevimbra", "tislelizumab", "PD-1", "ESCC二线治疗", "NMPA", "new_drug", date(2024,3,20), gastric_tag, "NCT03430843", 39000105),
("Opdualag", "nivolumab+relatlimab", "PD-1+LAG-3", "不可切除/转移性黑色素瘤", "FDA", "new_drug", date(2022,3,18), melanoma_tag, "NCT03470922", 39000113),
("Imjudo + Imfinzi", "tremelimumab+durvalumab", "CTLA-4+PD-L1", "不可切除HCC一线", "FDA", "new_drug", date(2022,10,21), liver_tag, "NCT03298451", 39000138),
]
for dn, gn, target, ind, agency, at, ad, ct, nct, pmid in drugs:
db.add(DrugApproval(id=uid(), drug_name=dn, generic_name=gn, target=target, indication=ind,
approval_agency=agency, approval_type=at, approval_date=ad,
cancer_type_tag_id=ct, pivotal_trial_nct=nct, pivotal_trial_pmid=pmid))
print(f" Drug approvals: {len(drugs)} records")
# 指南种子数据
guidelines = [
("NCCN", lung_tag, "2025.v3", date(2025,5,1), "osimertinib+chemo 1类推荐; amivantamab+lazertinib新增; 围术期免疫治疗扩展"),
("NCCN", breast_tag, "2025.v2", date(2025,3,15), "T-DXd HER2低表达1类; sacituzumab govitecan HR+后线1类"),
("NCCN", liver_tag, "2025.v1", date(2025,2,1), "atezo+bev 1L; durva+treme 1L; lenva+pembro 1L"),
("CSCO", lung_tag, "2025", date(2025,4,20), "更新驱动基因阳性NSCLC治疗路径; 新增国产PD-1一线推荐"),
("CSCO", gastric_tag, "2025", date(2025,3,10), "胃癌免疫治疗一线推荐扩展; 靶向治疗新增CLDN18.2"),
("ESMO", lung_tag, "2025", date(2025,6,1), "EGFR突变一线方案更新; 寡转移SBRT证据升级"),
("NHC", liver_tag, "2024", date(2024,12,15), "原发性肝癌诊疗指南(2024版) - PD-1/PD-L1联合TKI一线首选"),
]
for src, ct, ver, pd, summary in guidelines:
gv = GuidelineVersion(id=uid(), guideline_source=src, cancer_type_tag_id=ct,
version=ver, publish_date=pd, change_summary_zh=summary)
db.add(gv)
await db.flush()
print(f" Guidelines: {len(guidelines)} records")
# 指南证据链种子数据
guid_ev_map = {
("NCCN", "2025.v3"): [
("39000101", "Osimertinib+化疗作为EGFR突变NSCLC一线首选（1类推荐）", "1A", "1L"),
("39000115", "Amivantamab+Lazertinib作为EGFR突变NSCLC一线可选方案", "1A", "1L"),
("39000106", "辅助Alectinib用于ALK阳性NSCLC（1类推荐）", "1A", "adjuvant"),
],
("NCCN", "2025.v2"): [
("39000103", "T-DXd用于HER2低表达转移性乳腺癌（1类推荐）", "1A", "2L"),
("39000108", "CDK4/6抑制剂+ET作为HR+/HER2- mBC一线首选", "1A", "1L"),
],
}
evidence_count = 0
for (src, ver), ev_list in guid_ev_map.items():
gv = (await db.execute(select(GuidelineVersion).where(
GuidelineVersion.guideline_source == src, GuidelineVersion.version == ver))).scalar()
if not gv: continue
for pmid_str, rec, level, line in ev_list:
lit = (await db.execute(select(GlobalLiterature).where(GlobalLiterature.pmid == int(pmid_str)))).scalar()
if lit:
db.add(GuidelineEvidence(id=uid(), guideline_version_id=gv.id, literature_id=lit.id,
recommendation=rec, recommendation_level=level, treatment_line=line))
evidence_count += 1
print(f" Guideline evidence: {evidence_count} links")
await db.commit()
# 生成 Feed（复用同一个 session）
print(" Generating feeds...")
async with async_session() as db2:
feeds = await generate_all_feeds(db2)
print(f" Feeds generated: {feeds}")
print("=== Done ===")
if __name__ == '__main__':
asyncio.run(main())
Reference in New Issue View Git Blame Copy Permalink